Suchergebnisse - "Personeni, Nicola"

PubPharm (4)

1

Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma

enthalten in: The Lancet. Oncology | 2021

von Personeni, N. | Rimassa, L.

CommentOn: Lancet Oncol. 2021 Jul;22(7):991-1001. - PMID 34051880

2

Shaping the landscape of immune oncology in hepatocellular carcinoma

enthalten in: The Lancet. Oncology | 2018

von Personeni, N. | Rimassa, L.

CommentOn: Lancet Oncol. 2018 Jul;19(7):940-952. - PMID 29875066

3

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC) : a final analysis of a phase 3, randomised, placebo-controlled study

enthalten in: The Lancet. Oncology | 2018

von Rimassa, L. | Assenat, E. | Peck-Radosavljevic, M. | +27

CommentIn: Lancet Oncol. 2018 May;19(5):591-592. - PMID 29625880

4

Tivantinib for second-line treatment of advanced hepatocellular carcinoma : a randomised, placebo-controlled phase 2 study

enthalten in: The Lancet. Oncology | 2013

von Santoro, A. | Rimassa, L. | Borbath, I. | +25

CommentIn: Lancet Oncol. 2013 Jan;14(1):7-8. - PMID 23182626

1
[1]